Assessing Production And Stability For Current And Emerging Antibody Drug Conjugate Platforms

Antibody-drug conjugates (ADCs) with nearly identical antibody sequences—up to 90% similarity—can behave very differently depending on their linker, payload, and formulation choices. These variables significantly impact therapeutic performance, making thorough characterization essential. A range of analytical techniques is now being used to uncover these differences and ensure ADCs meet quality and efficacy standards. Intact Mass Spectrometry helps determine Drug-to-Antibody Ratio (DAR), while peptide mapping reveals how payloads are distributed across the molecule. Infrared spectroscopy provides insight into secondary structure, and absolute absorbance measurements assess structural similarity between ADCs. To evaluate physical stability, Dynamic Light Scattering (DLS) is used to detect aggregation, and Differential Scanning Calorimetry (DSC) measures thermal stability. Together, these methods offer a comprehensive view of ADC behavior, helping researchers and developers make informed decisions about formulation and design. For teams working in ADC development or quality control, understanding these tools is key to optimizing therapeutic outcomes.

Watch the full webinar to see how these techniques are applied in real-world scenarios.